Clinical Uses of MB-840 Highlighted at Contrast Media Research Conference.SAN DIEGO--(BW HealthWire)--Sept. 15, 1999-- Molecular Biosystems Molecular BioSystems is a peer reviewed scientific journal published monthly by the Royal Society of Chemistry. It publishes original (primary) research and review articles that have a particular focus at the interface between chemistry, the -omic sciences and systems Inc. (NYSE NYSE See: New York Stock Exchange :MB) reported today that MB-840, a unique liver-specific computed tomography Computed tomography (CT scan) X rays are aimed at slices of the body (by rotating equipment) and results are assembled with a computer to give a three-dimensional picture of a structure. (CT) contrast agent under development, is featured at the Biannual bi·an·nu·al adj. 1. Happening twice each year; semiannual. 2. Occurring every two years; biennial. bi·an Contrast Media Research Conference in Woodstock, Vermont Woodstock is a town in Windsor County, Vermont, in the United States. As of the 2000 census, the town population was 3,232. Woodstock has the twentieth highest per-capita incomes of Vermont towns as reported by the United States Census, and a high percentage of homes owned this week. This meeting brings academic and corporate scientists from around the world together to discuss the latest developments in contrast media. Animal studies have demonstrated that MB-840 could have broad uses for detecting and monitoring primary and metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. liver tumors as small as 1-2 millimeters in size and other diseases of the hepatobiliary system. By comparison, water-soluble CT contrast agents often have difficulty accurately detecting tumors smaller than about 20 millimeters. "We are aggressively moving ahead with the development of this agent and anticipate starting clinical trials by next year," commented Howard Dittrich M.D., executive vice president of MBI MBI Management Buy-In MBI Moody Bible Institute MBI Mathematical Biosciences Institute MBI Modular Building Institute MBI Mechanical Breakdown Insurance MBI Molecular Biology Institute MBI Maslach Burnout Inventory (psychometrics) . "MB-840's ability to detect such small liver tumors and the outline biliary tree is expected to dramatically influence the options available to clinicians for treating patients with hepatobiliary disease," he further stated. Abstracts being presented include hepatobiliary imaging and biodistribution results with MB-840 in normal and diseased animals. Also being discussed is the imaging efficacy of various MB-840 formulations in normal animals. Abstracts and discussions from the meeting will be published in a future issue of Academic Radiology. MBI, based in San Diego, is a world leader in developing contrast agents for diagnostic imaging. Its innovative product, OPTISON(R), improves diagnosis of heart disease through clearer ultrasound images. Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties. Among the factors that could result in a materially different outcome are: actual results of preclinical or clinical trials of the product for any of the uses stated above; the failure to gain regulatory approval for a product based on this technology; the inherent uncertainties accompanying the development of new products; and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. For More Information on Molecular Biosystems by Fax, Dial 888/329-4007, or Visit its Web site: www.mobi.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion